Abstract 1876P
Background
Societal beliefs about cancer can impact how patients perceive their disease generating cancer stigma (CS) with risk of emotional distress especially in Arab countries where cancer remains a taboo. This study aimed to evaluate aspects of CS according to Tunisian cancer patients, explore risk factors and describe the impact on mental health.
Methods
The study was a cross-sectional questionnaire-based study, conducted between February and April 2023, including 100 patients treated for cancer regardless of gender, type or stage. We developed the questionnaire by adapting items from the “Cancer stigma scale” using questions grouped in three domains: impossibility of recovery, stereotypes of cancer patients and experience of social discrimination. Depression and anxiety were evaluated by using the “Hospital Anxiety and Depression Scale”.
Results
Median age was 50 years old, 75% of patients were women. On average, patients were surveyed 20.48 months after diagnosis. Patients reported at least one form of CS in 57% of cases. They believed in the impossibility of recovery after cancer experience in 47% of cases. Forty percent of patients held stereotypical views of themselves: 48% endorsed that cancer patients would have a difficult time having sexual intimacy which was the item with the highest mean (2.45) among all questions. Thirty four percent of patients reported social discrimination on grounds of cancer: by family/spouse in 31%, at the workplace in 15% and by friends/neighbors in 13% of cases. Cancer stigma was significantly more perceived by patients with low socioeconomic status (OR= 3.74 [1.42-9.82]), living in rural areas (OR=26 [3.38-205] and with advanced stage disease (OR=4.2 [1.67-10.5]). Forty percent of patients reported significant depressive symptoms and 47% significant anxiety symptoms. Patients who experienced CS were 4.27 times more likely to have depression (p <0.001) and 3.57 times more probably to be anxious (p <0.001) than patients with positive attitudes.
Conclusions
Despite increased awareness, cancer patients had high levels of CS with negative impact on mental health. These results ring the alarm bell to change societal beliefs and to help patients perceive “better” their disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05